Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3b3dcae7fce2aa3f150d6c6af70554f9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a72f415fa5f1f3900fd6ce0c82fe5e4a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_688a2dbbc6adf6dfc11fe2874a5f9e74 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4355 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4355 |
filingDate |
2004-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1dbcae9d246732a77d0b7f981f74f510 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57aafa602953f360018fd53949f60a25 |
publicationDate |
2005-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2005021039-A1 |
titleOfInvention |
Combination of cicletanine and an oral antidiabetic and/or blood lipid-lowering agent for treating diabetes and metabolic syndrome |
abstract |
Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing complications in patients with diabetes and/or metabolic syndrome. More particularly, aspects of the present invention are related to using a combination of cicletanine and an oral antidiabetic agent for treating and/or preventing complications (including microalbuminuria, nephropathies, retinopathies and other complications) in patients with diabetes or metabolic syndrome. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103040800-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1804795-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008085872-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1804795-A4 |
priorityDate |
2003-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |